Budd-Chiari Syndrome can be treated with anticoagulants

In Budd-Chiari Syndrome, extension of thrombosis into the splanchnic venous bed is related to the number of etiological factors, and results in the latest American Journal of Gastroenterology support a liberal use of anticoagulants.

The team observed that the 5-year survival was 59% in Group 2 versus 85% in Group 1.

Survival tended to be worse in patients in Group 1 as compared to patients in Group 2 presenting without spleno-mesenteric vein thrombosis.

Dr Murad's team concluded, “In Budd-Chiari Syndrome, extension of thrombosis into the splanchnic venous bed was significantly related to the number of etiological factors, and was associated with poor outcome.”

“These results strongly support a liberal use of anticoagulants, which so far had been widely debated.”